Drugs that contain Oxybutynin
1. Gelnique 3% patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7029694 | ALLERGAN | Compositions and methods for transdermal oxybutynin therapy |
Apr, 2020
(3 years ago) | |
| US7179483 | ALLERGAN | Compositions and methods for transdermal oxybutynin therapy |
Apr, 2020
(3 years ago) | |
| US8241662 | ALLERGAN | Unoccluded topical oxybutynin gel composition and methods for transdermal oxybutynin therapy |
Apr, 2020
(3 years ago) | |
| US7198801 | ALLERGAN | Formulations for transdermal or transmucosal application |
Jun, 2022
(1 year, 9 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 07, 2014 |
Market Authorisation Date: 07 December, 2011
Treatment: Treatment of patients with an overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence
Dosage: GEL, METERED;TRANSDERMAL
More Information on Dosage
GELNIQUE 3% family patents
2. Oxytrol patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7179483 | ALLERGAN | Compositions and methods for transdermal oxybutynin therapy |
Apr, 2020
(3 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5601839 | ALLERGAN | Triacetin as a penetration enhancer for transdermal delivery of a basic drug |
Apr, 2015
(8 years ago) | |
| US5834010 | ALLERGAN | Triacetin as a penetration enhancer for transdermal delivery of a basic drug |
Apr, 2015
(8 years ago) | |
| US7081249 | ALLERGAN | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
Apr, 2020
(3 years ago) | |
| US7081250 | ALLERGAN | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
Apr, 2020
(3 years ago) | |
| US7081251 | ALLERGAN | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
Apr, 2020
(3 years ago) | |
| US7081252 | ALLERGAN | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
Apr, 2020
(3 years ago) | |
| US6743441 | ALLERGAN | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
Apr, 2020
(3 years ago) | |
Market Authorisation Date: 26 February, 2003
Treatment: Treatment of patients with an overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence
Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL
How can I launch a generic of OXYTROL before it's drug patent expiration?
More Information on Dosage
OXYTROL family patents
3. Oxytrol For Women patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5601839 | ABBVIE | Triacetin as a penetration enhancer for transdermal delivery of a basic drug |
Apr, 2015
(8 years ago) | |
| US5834010 | ABBVIE | Triacetin as a penetration enhancer for transdermal delivery of a basic drug |
Apr, 2015
(8 years ago) | |
| US7081252 | ABBVIE | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
Apr, 2020
(3 years ago) | |
| US6743441 | ABBVIE | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
Apr, 2020
(3 years ago) | |
| US7081249 | ABBVIE | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
Apr, 2020
(3 years ago) | |
| US7081250 | ABBVIE | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
Apr, 2020
(3 years ago) | |
| US7081251 | ABBVIE | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
Apr, 2020
(3 years ago) | |
| US7179483 | ABBVIE | Compositions and methods for transdermal oxybutynin therapy |
Apr, 2020
(3 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 25, 2016 |
Market Authorisation Date: 25 January, 2013
Treatment: Treatment of patients with an overactive bladder
Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL
More Information on Dosage
OXYTROL FOR WOMEN family patents